Skip Navigation
Skip Navigation

Professor Emeritus Alan Mackay-Sim takes home 2017 'Australian Of The Year' Award.

Thu 26, Jan 2017


Professor Emeritus Alan Mackay-Sim taking home 2017 'Australian Of The Year' award.

This week will go down in the history books as a milestone occasion for the Perry Cross Spinal Research Foundation following Professor Emeritus Alan Mackay-Sim being awarded the prestigious 2017 'Australian Of The Year'.

Prof. Mackay-Sim led the world first Phase 1 Clinical Trial that demonstrated that a 'Olfactory Cell Transplantation (OCT)' is safe for use in humans and shows restoration of function following a spinal cord injury and continues to work closely with our team of scientists to progress the global study here in Queensland.  The PCSRF has committed over $500,000 in recent years to progress the OCT research and continues to play an integral role in its development.

The Australian of the Year Award is renowned as one of Australia's most esteemed accolades and recognises inspiring individuals who lead as role models for their communities, their state, and the nation.

Perry says the Professor's inspirational work gives hope to thousands of Australians living with paralysis and the award substantially raises the awareness of the world-class secondary stage of the trial, that the PCRSF is funding.

"This is a massive milestone for Prof. Mackay-Sim, for Australia and for the thousands of people living with spinal cord injuries," he said.

"The entire foundation and our loyal members are thrilled for Prof. Mackay-Sim being named Australian Of The Year and we look forward to congratulating him in person when he returns from Canberra.

"The award puts a whole new spotlight on the research being undertaken to find a cure for paralysis - and the next phase of the study, a planned human clinical trial that we are working tirelessly to fund, is looking more promising than ever before.

"Alan's ground-breaking research laid the foundation for the OCT and that certainly lights a fire within all of us living with paralysis. His scientific nous and strategic direction continues to play an integral role in overseeing the highly experienced team of scientists at the Griffith Institute for Drug Discovery at Griffith University, who are progressing the OCT's next phase."



< Back